• Hajime Nakamura, Kohichi Takada, Makoto Emori, Naotaka Hayasaka, and Shintaro Sugita.
• Department of Medical Oncology, Sapporo Medical University School of Medicine, Japan.
• Intern. Med. 2022 Dec 1; 61 (23): 361736213617-3621.

AbstractWe herein report a rare case of unresectable liposarcoma that showed a complete response to eribulin. Furthermore, a low expression of phosphorylated AKT (p-AKT) on an immunohistological evaluation was observed. This result is consistent with our previous preclinical study that demonstrated the significance of p-AKT signaling for eribulin resistance in multiple subtypes of soft tissue sarcoma (STS) cells. This case highlights the potential benefits of eribulin as well as the mechanism underlying resistance to eribulin in patients with unresectable or metastatic STS, especially liposarcoma.

10 keywords...

hide…